Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy

Robin Demuynck; Yanou Engelen; André G Skirtach; Stefaan C De Smedt; Ine Lentacker; Dmitri V Krysko

doi:10.1016/j.trecan.2024.03.003

Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy

Trends Cancer. 2024 Mar 28:S2405-8033(24)00052-9. doi: 10.1016/j.trecan.2024.03.003. Online ahead of print.

Authors

Robin Demuynck¹, Yanou Engelen², André G Skirtach³, Stefaan C De Smedt², Ine Lentacker², Dmitri V Krysko⁴

Affiliations

¹ Cell Death Investigation and Therapy Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Ghent University, Faculty of Medicine and Health Sciences, 9000 Ghent, Belgium; Cancer Research Institute Ghent, 9000 Ghent, Belgium.
² Laboratory of General Biochemistry and Physical Pharmacy, Ghent Research Group on Nanomedicine, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
³ Cancer Research Institute Ghent, 9000 Ghent, Belgium; NanoBioTechnology Laboratory, Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium.
⁴ Cell Death Investigation and Therapy Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Ghent University, Faculty of Medicine and Health Sciences, 9000 Ghent, Belgium; Cancer Research Institute Ghent, 9000 Ghent, Belgium. Electronic address: dmitri.krysko@ugent.be.

PMID: 38553361
DOI: 10.1016/j.trecan.2024.03.003

Abstract

Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.

Keywords: DAMPs; anticancer immunity; apoptosis; necroptosis; pyroptosis and ferroptosis nanoparticles.